Pharma Mar (OTCMKTS:PHMMF) Sees Significant Growth in Short Interest

Pharma Mar (OTCMKTS:PHMMF) saw a large increase in short interest in August. As of August 31st, there was short interest totaling 8,682 shares, an increase of 9,136.2% from the August 15th total of 94 shares. Based on an average daily volume of 36 shares, the short-interest ratio is presently 241.2 days. Approximately 0.0% of the company’s shares are sold short.

Pharma Mar Stock Performance

OTCMKTS:PHMMF remained flat at $94.60 during trading hours on Thursday. 3 shares of the company’s stock were exchanged, compared to its average volume of 20. Pharma Mar has a 1-year low of $77.41 and a 1-year high of $110.40. The company has a current ratio of 3.02, a quick ratio of 2.44 and a debt-to-equity ratio of 0.14. The stock has a fifty day moving average price of $88.37 and a 200-day moving average price of $93.91.

Wall Street Analyst Weigh In

PHMMF has been the subject of a number of research analyst reports. Zacks Research upgraded Pharma Mar to a “hold” rating in a report on Monday, June 15th. Chardan Capital upgraded Pharma Mar to a “strong-buy” rating in a report on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Pharma Mar currently has a consensus rating of “Buy”.

Pharma Mar Company Profile

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.